- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles1 new
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HGSI Market Currents
more »
-
Friday 3:06 PM Human Genome (HGSI +0.6%) should still see a higher bid , says Baird, noting they "remain confident" that a higher bid will emerge despite Glaxo's (GSK +0.3%) indication it will suspend the tender offer while the company's poison pill is in effect. The firm met with management and said their calculations point to a bid closer to $20.
Comment![Healthcare]
- Thursday 12:07 PM Human Genome (HGSI -2.4%) slips on a BMO downgrade to Market Perform. THe firm believes the risk of GlaxoSmithKline (GSK) dropping its offer has increased and the likelihood of an significant price increase or a contingent value right for darapladib has been reduced. The firm lowers its price target to $13 from $17. [Healthcare, On the Move]
- Wednesday 8:55 AM GSK (GSK) ammends the conditions of its $2.6B tender offer for Human Genome (HGSI), requiring that the latter redeem or invalidate its poison pill. [Healthcare, M&A]
HGSI in Focus
more »
HGSI Related Articles
more »
HGSI News
more »
-
at CNBC.com (May 17, 2012)
-
at CNBC.com (May 9, 2012)
-
at CNBC.com (Apr 23, 2012)
-
at MarketWatch.com (Apr 19, 2012)
-
at CNBC.com (Apr 19, 2012)
HGSI Press Releases and Filings
more »
-
Business Wire (May 17, 2012)
-
Business Wire (May 17, 2012)
-
Business Wire (May 9, 2012)
-
Business Wire (Apr 24, 2012)
-
Business Wire (Apr 20, 2012)
HGSI Latest Transcript
more »
-
Tue, Apr 24
HGSI Cramer
more »
HGSI Instablog posts
more »
HGSI vs. ETF Alternatives
Company Description
Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More